Gene: PCSK9

255738
FH3|HCHOLA3|LDLCQ1|NARC-1|NARC1|PC9
proprotein convertase subtilisin/kexin type 9
protein-coding
1p32.3
Ensembl:ENSG00000169174 MIM:607786 Vega:OTTHUMG00000008136 UniprotKB:Q8NBP7
NG_009061.1
PubMed
0   ANCO-SNPs
ND
22   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.632e-3 (AD)  5.348e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC9A50.596
PASK0.582
EFCAB120.554
TMEM74B0.532
RAD54L0.521
GAS2L20.52
FER1L50.518
DNAH100.516
FHDC10.504
GPR550.503

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DIO2-0.313
SLC25A48-0.292
NXT2-0.291
MBNL3-0.291
BTBD17-0.283
NCKAP5-0.283
ZNF98-0.281
PYGM-0.271
ZNF501-0.269
ASCL1-0.268

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB09302AlirocumabBiotechDrug1245916-14-6ApprovedTarget
DB09303EvolocumabBiotechDrug1256937-27-5ApprovedEnzyme
ID Drug Name Action PubMed
C0184061-(3-trifluoromethylphenyl)piperazine1-(3-trifluoromethylphenyl)piperazine results in increased expression of PCSK9 mRNA26821219
C47781915-deoxyprostaglandin J215-deoxyprostaglandin J2 results in increased expression of PCSK9 mRNA22593575
C47781915-deoxyprostaglandin J215-deoxyprostaglandin J2 results in increased expression of PCSK9 protein22593575
C0780921-piperonylpiperazine1-piperonylpiperazine results in increased expression of PCSK9 mRNA26821219
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of PCSK9 mRNA"25510870
C0939732-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased expression of PCSK9 protein22593575
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of PCSK9 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of PCSK9 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of PCSK9 mRNA"25510870
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of PCSK9 mRNA"21346803
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of PCSK9 mRNA"25510870
C0065512-amino-2-methyl-1-propanol2-amino-2-methyl-1-propanol results in increased expression of PCSK9 mRNA25088246
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane affects the expression of PCSK9 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C0207389,10-dihydro-9,10-dihydroxybenzo(a)pyrene"9,10-dihydro-9,10-dihydroxybenzo(a)pyrene results in decreased expression of PCSK9 mRNA"26238291
C496492abrineabrine results in decreased expression of PCSK9 mRNA22595364
D000079AcetaldehydeAcetaldehyde affects the expression of PCSK9 mRNA22634333
D000082AcetaminophenAcetaminophen results in decreased expression of PCSK9 mRNA21420995|2906747
C014949acetylhydrazineacetylhydrazine results in increased expression of PCSK9 mRNA15282401
D016604Aflatoxin B1Aflatoxin B1 affects the expression of PCSK9 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of PCSK9 mRNA21632981|2164198
D000452AldrinAldrin results in increased expression of PCSK9 mRNA18579281
D000638AmiodaroneAmiodarone results in increased expression of PCSK9 mRNA19774075
C006632arsenic trioxidearsenic trioxide results in decreased expression of PCSK9 mRNA26705709
C487081belinostatbelinostat results in decreased expression of PCSK9 mRNA27188386
D019324beta-NaphthoflavoneAHR protein affects the reaction [beta-Naphthoflavone results in decreased expression of PCSK9 mRNA]22234961
D019324beta-Naphthoflavonebeta-Naphthoflavone results in decreased expression of PCSK9 mRNA22234961
D019324beta-Naphthoflavone[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PCSK9 mRNA18164116
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PCSK9 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PCSK9 mRNA19770486
D004958EstradiolEstradiol results in decreased expression of PCSK9 mRNA20106945|2163298
D001629BezafibrateBezafibrate results in increased expression of PCSK9 protein21411093
C006780bisphenol Abisphenol A results in decreased expression of PCSK9 mRNA26364221
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PCSK9 mRNA28628672
C006780bisphenol Abisphenol A affects the methylation of PCSK9 promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of PCSK9 mRNA25181051
C006780bisphenol Abisphenol A inhibits the reaction [Triiodothyronine results in decreased expression of PCSK9 mRNA]19228888
D002110CaffeineCaffeine results in decreased expression of PCSK9 mRNA25868845
D002220CarbamazepineCarbamazepine results in decreased expression of PCSK9 mRNA21123845
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of PCSK9 mRNA26272509
D002922CiguatoxinsCiguatoxins affects the expression of PCSK9 mRNA18353800
C018021cobaltous chloridecobaltous chloride results in decreased secretion of PCSK9 protein22079246
D003300Copper[NSC 689534 binds to Copper] which results in decreased expression of PCSK9 mRNA20971185
D019327Copper SulfateCopper Sulfate results in decreased expression of PCSK9 mRNA19549813
D019327Copper SulfateCopper Sulfate results in increased expression of PCSK9 mRNA18579281
D003474CurcuminCurcumin affects the expression of PCSK9 mRNA27208389
D016572CyclosporineCyclosporine results in decreased expression of PCSK9 mRNA20106945|2163298
D016572CyclosporineCyclosporine results in increased expression of PCSK9 mRNA27989131
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PCSK9 mRNA28628672
D002945CisplatinCisplatin results in decreased expression of PCSK9 mRNA22023808
D004008DiclofenacDiclofenac results in increased expression of PCSK9 mRNA26934552
D004041Dietary FatsDietary Fats affects the expression of PCSK9 mRNA19680557
D004041Dietary FatsDietary Fats results in decreased expression of PCSK9 mRNA18457598|2260994
D004041Dietary FatsDietary Fats results in increased expression of PCSK9 mRNA25016146
D004041Dietary FatsDietary Fats results in decreased expression of PCSK9 mRNA23524313
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of PCSK9 mRNA24535843
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PCSK9 mRNA18164116
D004052DiethylnitrosamineDiethylnitrosamine results in decreased expression of PCSK9 mRNA19638242
D0198131,2-Dimethylhydrazine"1,2-Dimethylhydrazine results in decreased expression of PCSK9 mRNA"27840820
D000069438Ezetimibe[Simvastatin co-treated with Ezetimibe] results in increased expression of PCSK9 mRNA17980884
D005228Fatty Acids, Essential"Fatty Acids, Essential deficiency results in increased expression of PCSK9 mRNA"23333450
D011345FenofibrateFenofibrate results in increased expression of PCSK9 protein21411093
C061365flusilazoleflusilazole results in increased expression of PCSK9 mRNA28263823
C065180fluvastatin[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin19773416
C056507gemcitabinegemcitabine results in increased expression of PCSK9 mRNA17039268
D005897GlafenineGlafenine results in increased expression of PCSK9 mRNA24136188
D005978GlutathioneGlutathione deficiency results in decreased expression of PCSK9 mRNA20621112
C029424hydrazinehydrazine results in increased expression of PCSK9 mRNA15282401
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PCSK9 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PCSK9 mRNA28628672
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of PCSK9 mRNA26752646
C410337K 7174K 7174 results in decreased expression of PCSK9 mRNA24086573
D007654KetoconazoleKetoconazole results in increased expression of PCSK9 mRNA28263823
D008070LipopolysaccharidesLipopolysaccharides results in increased expression of PCSK9 mRNA18638454
C042720mercuric bromidemercuric bromide results in decreased expression of PCSK9 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of PCSK9 mRNA28001369
C004925methylmercuric chloridemethylmercuric chloride affects the expression of PCSK9 mRNA21613230
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of PCSK9 mRNA26011545
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of PCSK9 mRNA"24389112
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of PCSK9 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of PCSK9 mRNA"25620056
C461488N-benzylpiperazineN-benzylpiperazine results in increased expression of PCSK9 mRNA26821219
C558013NSC 689534[NSC 689534 binds to Copper] which results in decreased expression of PCSK9 mRNA20971185
D009966OrphenadrineOrphenadrine affects the expression of PCSK9 mRNA23665939
D000073878Palm OilPalm Oil affects the expression of PCSK9 mRNA19680557
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of PCSK9 mRNA"25510870
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in decreased expression of PCSK9 mRNA26705709
D010416PentachlorophenolPentachlorophenol results in increased expression of PCSK9 mRNA23892564
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of PCSK9 protein26879310
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of PCSK9 mRNA26272509
C060836pioglitazonepioglitazone promotes the reaction [PPARG protein results in increased expression of PCSK9 mRNA]22593575
C060836pioglitazonepioglitazone results in increased expression of PCSK9 mRNA22593575
C060836pioglitazonepioglitazone results in increased expression of PCSK9 protein22593575
C060836pioglitazone[pioglitazone co-treated with U 0126] results in increased secretion of PCSK9 protein22593575
C060836pioglitazonepioglitazone results in increased expression of PCSK9 protein22593575
D017035PravastatinPravastatin results in increased expression of PCSK9 mRNA27225895
D017035PravastatinPravastatin results in increased expression of PCSK9 mRNA27225895
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in decreased expression of PCSK9 mRNA28903501
D011441PropylthiouracilPropylthiouracil results in increased expression of PCSK9 mRNA24780913
D011794QuercetinQuercetin results in decreased expression of PCSK9 mRNA21632981
C059514resveratrolresveratrol results in increased expression of PCSK9 mRNA22153697
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of PCSK9 mRNA25895662
D012834SilverSilver results in decreased expression of PCSK9 mRNA26014281
D019821Simvastatin[Simvastatin co-treated with Ezetimibe] results in increased expression of PCSK9 mRNA17980884
C075117squalestatin 1squalestatin 1 results in increased expression of PCSK9 mRNA27225895
C075117squalestatin 1squalestatin 1 results in increased expression of PCSK9 mRNA27225895
C025462sulindac sulfidesulindac sulfide results in decreased expression of PCSK9 mRNA16184548
D014284Triiodothyroninebisphenol A inhibits the reaction [Triiodothyronine results in decreased expression of PCSK9 mRNA]19228888
D014284TriiodothyronineTriiodothyronine results in decreased expression of PCSK9 mRNA19228888
C013698tallowtallow affects the expression of PCSK9 mRNA19680557
D013629TamoxifenTamoxifen results in decreased expression of PCSK9 mRNA25123088
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of PCSK9 mRNA20106945|2163298
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PCSK9 mRNA28238261|2892240
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PCSK9 mRNA22298810
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of PCSK9 mRNA28065790
D014212TretinoinTretinoin results in increased expression of PCSK9 mRNA28689802
D014241TrichloroethyleneTrichloroethylene results in decreased expression of PCSK9 mRNA25549359
C012589trichostatin Atrichostatin A results in decreased expression of PCSK9 mRNA24935251
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of PCSK9 mRNA"26179874
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of PCSK9 mRNA29024780
C057693troglitazonetroglitazone results in decreased expression of PCSK9 mRNA25572481
D014425TurpentineTurpentine results in increased expression of PCSK9 mRNA18638454
C113580U 0126U 0126 promotes the reaction [PPARG protein results in increased expression of PCSK9 protein]22593575
C113580U 0126U 0126 results in increased expression of PCSK9 protein22593575
C113580U 0126[pioglitazone co-treated with U 0126] results in increased secretion of PCSK9 protein22593575
C113580U 0126U 0126 results in increased expression of PCSK9 protein22593575
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of PCSK9 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of PCSK9 mRNA23179753|2627250
D014635Valproic AcidValproic Acid affects the expression of PCSK9 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of PCSK9 gene25560391
D014752Vinyl ChlorideVinyl Chloride results in increased expression of PCSK9 mRNA18579281
C088658zoledronic acidzoledronic acid results in increased expression of PCSK9 mRNA24714768
D015054ZymosanZymosan results in increased expression of PCSK9 mRNA18638454

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003723RNA binding-HDA22658674  
GO:0004252serine-type endopeptidase activity-IDA12552133  
GO:0005515protein binding-IPI17461796  18799458  22081141  22493497  22580899  22848640  
25613181  
GO:0019871sodium channel inhibitor activity-IDA22493497  
GO:0030169low-density lipoprotein particle binding-ISS-  
GO:0030547receptor inhibitor activity-IDA22848640  
GO:0034185apolipoprotein binding-ISS-  
GO:0034189very-low-density lipoprotein particle binding-ISS-  
GO:0034190apolipoprotein receptor binding-IDA18039658  
GO:0043621protein self-association-IDA18197702  
GO:0050750low-density lipoprotein particle receptor binding-IDA17080197  
GO:0050750low-density lipoprotein particle receptor binding-IPI17452316  22848640  
GO:0070326very-low-density lipoprotein particle receptor binding-IDA18039658  
GO ID GO Term Qualifier Evidence PubMed
GO:0001822kidney development-ISS12552133  
GO:0001889liver development-ISS12552133  
GO:0001920negative regulation of receptor recycling-IDA17452316  22848640  
GO:0002092positive regulation of receptor internalization-IDA17328821  
GO:0006641triglyceride metabolic process-IEA-  
GO:0006644phospholipid metabolic process-IEA-  
GO:0006915apoptotic process-IEA-  
GO:0007041lysosomal transport-IDA17452316  
GO:0008203cholesterol metabolic process-IEA-  
GO:0009267cellular response to starvation-ISS16407292  
GO:0010469regulation of signaling receptor activity-IDA17328821  
GO:0010989negative regulation of low-density lipoprotein particle clearance-IDA17328821  22848640  
GO:0016540protein autoprocessing-IDA14622975  
GO:0022008neurogenesis-ISS12552133  
GO:0030182neuron differentiation-ISS12552133  
GO:0032802low-density lipoprotein particle receptor catabolic process-IDA16912035  18197702  
GO:0032802low-density lipoprotein particle receptor catabolic process-TAS-  
GO:0032805positive regulation of low-density lipoprotein particle receptor catabolic process-IDA22848640  
GO:0032869cellular response to insulin stimulus-ISS12552133  
GO:0034383low-density lipoprotein particle clearance-TAS-  
GO:0042157lipoprotein metabolic process-IEA-  
GO:0042632cholesterol homeostasis-IMP17170371  
GO:0043523regulation of neuron apoptotic process-ISS-  
GO:0043525positive regulation of neuron apoptotic process-IMP17051583  
GO:0043687post-translational protein modification-TAS-  
GO:0044267cellular protein metabolic process-TAS-  
GO:1905596negative regulation of low-density lipoprotein particle receptor binding-IDA22848640  
GO:1905598negative regulation of low-density lipoprotein receptor activity-IDA22848640  
GO:1905601negative regulation of receptor-mediated endocytosis involved in cholesterol transport-IDA22848640  
GO:2000272negative regulation of signaling receptor activity-IEA-  
GO:2000650negative regulation of sodium ion transmembrane transporter activity-IDA22493497  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005615extracellular space-IDA12552133  16912035  17080197  
GO:0005737cytoplasm-IDA22580899  
GO:0005764lysosome-IDA17461796  18039658  
GO:0005765lysosomal membrane-TAS-  
GO:0005769early endosome-IDA17461796  
GO:0005770late endosome-IDA17461796  18039658  
GO:0005783endoplasmic reticulum-IDA17461796  
GO:0005788endoplasmic reticulum lumen-TAS-  
GO:0005791rough endoplasmic reticulum-IEA-  
GO:0005794Golgi apparatus-IDA17461796  
GO:0005886plasma membrane-IDA18799458  
GO:0009986cell surface-IDA17461796  
GO:0030134COPII-coated ER to Golgi transport vesicle-IEA-  
GO:0031232extrinsic component of external side of plasma membrane-IC17328821  
GO:0036020endolysosome membrane-TAS-  
GO:0048471perinuclear region of cytoplasm-IDA18039658  
GO:1990666PCSK9-LDLR complex-IDA22848640  
GO:1990667PCSK9-AnxA2 complex-IDA22848640  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-174824Plasma lipoprotein assembly, remodeling, and clearanceTAS
R-HSA-381426Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)TAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-8866427VLDLR internalisation and degradationTAS
R-HSA-8957275Post-translational protein phosphorylationTAS
R-HSA-8964038LDL clearanceTAS
R-HSA-8964043Plasma lipoprotein clearanceTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24404629Familial Hypercholesterolemia (1993)Youngblom E-
26896437Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors. (2016 Mar 29)Leander KCirculation
27049268Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions. (2016)Wang SEur Rev Med Pharmacol Sci
17142622Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. (2006 Dec)Humphries SEJ Med Genet
27846466Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease. (2017 Jan 15)Hu DInt J Cardiol
23375686Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. (2013 Apr)Bertolini SAtherosclerosis
28167353Genetic risk analysis of coronary artery disease in Pakistani subjects using a genetic risk score of 21 variants. (2017 Mar)Shahid SUAtherosclerosis
22216278Large scale association analysis identifies three susceptibility loci for coronary artery disease. (2011)Saade SPLoS One
17550346The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. (2007 Dec)Scartezini MClin Sci (Lond)
22606049Interactions of several lipid-related gene polymorphisms and cigarette smoking on blood pressure levels. (2012)Yin RXInt J Biol Sci
22111029Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population. (2012)Setia NCardiol Res Pract
29754909Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. (2018 Jul 15)Liberale LInt J Cardiol
19191720The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. (2009)Hsu LAClin Chem Lab Med
26003826Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status. (2015 Dec)Li SJ Endocrinol Invest
26706651Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. (2016 May)Chan DCHeart Lung Circ
28353356Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. (2017 Jul)Rubba PEur J Prev Cardiol
28911508Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. (2017 Sep 19)Pastori DJ Am Coll Cardiol
27919350Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization. (2016 Nov - Dec)Zafrir BJ Clin Lipidol
26632531Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. (2016)Tada HCirc J
25904937PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies. (2015)Tran NTFront Genet
26508163Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. (2016 Feb 7)Ridker PMEur Heart J
27403140Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus. (2016 May)Wang MJ Geriatr Cardiol